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and outcomes related to respiratory infection events were assembled monthly. 
Cox regressions were performed to determine hazard ratios (HRs) for hospitaliza-
tion. RESULTS: 12,137 infants (57.6% male, mean (SD) birth weight = 1585 (621)g, 
mean (SD) GA = 31.0 (2.9) weeks) were recruited and GA was categorized according 
to completed weeks: ≤ 26 weeks, 27-28 weeks, 29-30 weeks, 31-32 weeks, and 33-35 
weeks. Risk of RIH (HR, 95%CI) was significantly lower only in premature infants 
with GA ≤ 26 weeks (HR= 0.6, 0.4-1.0, p = .04). Risk of RSVH was significantly higher 
in infants with GA ≤ 26 weeks (HR = 4.2, 2.3-7.8, p < .0005), 27-28 weeks (HR = 2.3, 
1.2-4.1, p = .008), and 29-30 weeks (HR = 1.8, 1.0-3.0, p = .04) using 31-32 WGA as 
the comparator. CONCLUSIONS: Infants ≤ 30 WGA who received palivizumab 
had a significantly higher hazard for RSVH than those > 30 weeks. Lower RSVH 
hazard ratios in infants with higher GAs (> 30 weeks) are in agreement with the 
efficacy of palivizumab in this cohort (> 80% reduction in RSVH [32-35 weeks], 
IMpact trial) demonstrating that premature infants with lower GA are at highest 
risk following prophylaxis.
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ModelINg SurvIval IMPact of HazardouS drINkINg aNd treatMeNt to 
reduce HazardouS drINkINg aMoNg INdIvIdualS wItH HIv INfectIoN: 
a MoNte carlo SIMulatIoN Model
Hu X., Cook R.L.
University of Florida, Gainesville, FL, USA
OBJECTIVES: Modifiable factors contributable to disease progression and survival 
among people with HIV infection are of particular importance for HIV research. 
Hazardous drinking is one such variable associated with delayed linkage in care, 
increased HIV disease progression, worsened comorbidities (e.g., liver diseases). 
Curtailing hazardous drinking may have important survival implications. Few stud-
ies have explored the relationship among hazardous drinking, alcohol treatment 
and survival. We developed a computer simulation model predicting the survival 
influence of hazardous drinking and usage of alcohol treatment among individu-
als with HIV infection. METHODS: We simulated cohorts of 50,000 antiretroviral-
naïve hazardous drinkers with newly diagnosed chronic HIV infection. The model 
incorporated the influence of ART and distinguished AIDS-related deaths and non-
AIDS-related deaths (CVD, Cancer, Liver, and others). We modeled the impact of 
hazardous drinking on survival via its influence on viral suppression, and subse-
quent AIDS-related deaths, and mortality of various non-AIDS-related deaths. The 
role of alcohol treatment on survival was mediated through changes in hazardous 
drinking. The simulation model was a probabilistic, Monte-Carlo model created 
by Microsoft Excel 2010, and Oracle Crystal Ball 11. RESULTS: Hazardous drinking 
substantially reduced mean survival years and increased risk of dying due to liver 
diseases. For patients aged 35, hazardous drinkers had an average of 2.9 years lower 
in expected life years compared with those without hazardous drinking (30.4 years 
vs. 33.3 years). Receipt of alcohol treatment, regardless of behavioral treatment or 
pharmacotherapy, saved an average of 0.3 to 1.2 years per hazardous drinker when 
utilization rate varying from 10% to 80%. CONCLUSIONS: This study quantified 
deleterious effect of hazardous drinking in survival and provided evidence sup-
porting the survival benefits of using alcohol treatment. Given the high prevalent of 
hazardous drinking among individuals with HIV infection, interventions to decrease 
alcohol use may have great public health implications.
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PHarMacoePIdeMIology of cloStrIdIal collageNaSe oINtMeNt for 
tHe treatMeNt of dIabetIc foot ulcerS IN outPatIeNt care SettINgS
Gilligan A.M., Waycaster C.R.
Smith & Nephew Inc., Fort Worth, TX, USA
OBJECTIVES: Identify patient and clinical characteristics in the diabetic foot 
ulcer (DFU) population and examine patterns of enzymatic debridement utiliza-
tion. METHODS: Retrospective, de-identified electronic medical records from 
2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS 
extracts records from 96 hospital-based outpatient wound centers. Patient, wound 
and encounter level characteristics were examined. The treatment of interest was 
enzymatic debridement with clostridial collagenase ointment (CCO). RESULTS: A 
total of 10,359 patients, 21,677 wounds, and 222,861 encounters for DFU were iden-
tified. The majority of patients was male (60.9%), Caucasian (63.5%), and reported 
Medicare as their primary insurance (51.1%). Of the 21,677 wounds, approximately 
16.9% received CCO (n= 3,670). Overall, the mean wound surface area was significantly 
larger (p< 0.0001) in DFUs treated with CCO (7.6cm2) compared to wounds not treated 
with CCO (5.4cm2), respectively. Wounds treated with CCO had significantly more 
(p< 0.001) debridements of all methods (5.4, SD= 6.3) relative to the overall population 
(4.3, SD= 6.1). Problems treated with CCO were significantly more likely (p< 0.0001) 
to have an infection (63.4%) compared to the overall DFU population (50.9%). The 
average number of visits where CCO was administered was 10.2 (SD= 9.7) and the 
average days of use with CCO was 53.2 days (SD= 68.9). The average number of CCO 
tubes used by patients was 2.4 (SD= 0.9). Mean days in service for CCO-treated wounds 
was 129.5 (SD= 149.1), which was significantly higher compared to days in service for 
non-CCO treated wounds (102.6, SD= 151.8). CONCLUSIONS: Wounds treated with 
CCO were larger, more likely to receive debridement of all methods, and more likely 
to be infected relative to the overall DFU population. Results from this analysis indi-
cate that health care providers are using CCO in more severe, difficult-to-heal DFUs.
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PHarMacoePIdeMIology of cloStrIdIal collageNaSe oINtMeNt for 
tHe treatMeNt of PreSSure ulcerS IN outPatIeNt care SettINgS
Gilligan A.M., Waycaster C.R.
Smith & Nephew Inc., Fort Worth, TX, USA
OBJECTIVES: Identify patient and clinical characteristics in the pressure ulcer (PU) 
population and examine patterns of enzymatic debridement utilization. METHODS: 
Retrospective, de-identified electronic medical records from 2007-2013 were extracted 
from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 
comparison using patient-level data suggests significantly higher SVR24 response 
rates for patients treated with simeprevir compared to telaprevir.
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treatMeNt of acute bacterIal SkIN aNd SkIN Structure INfectIoN 
(abSSSI) due to MetHIcIllIN-reSIStaNt StaPHylococcuS aureuS (MrSa)
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OBJECTIVES: Tedizolid is a novel oxazolidinone approved for the treatment of 
ABSSSI. A network meta-analysis (NMA) was conducted to estimate the relative 
effectiveness and safety of tedizolid compared to other antibacterials for suspected 
or documented MRSA-associated ABSSSI. METHODS: A systematic review identified 
relevant randomized controlled trials of tedizolid and other antibacterials approved 
to treat complicated skin infections (cSSSI, cSSTI, and ABSSSI) caused by suspected 
or documented MRSA in adults (vancomycin, linezolid, daptomycin, teicoplanin, 
tigecycline, ceftaroline, and telavancin). Two independent reviewers extracted 
study characteristics and outcomes, including clinical response at post-treatment 
evaluation (generally 7-14 days following therapy) and adverse events (AE)-related 
treatment discontinuations. Bayesian NMA was conducted for each outcome using 
fixed and random effects models. RESULTS: 3,618 records were identified. 15 trials 
met inclusion criteria. In fixed effect models, tedizolid had higher odds of clinical 
response at PTE or TOC than vancomycin (odds ratio [OR]: 1.6 [95% credible inter-
val: 1.1, 2.5]), corresponding to absolute response rates of 87% [9%, 100%] and 80% 
[5%, 100%], respectively. No statistically significant differences in odds of clinical 
response between tedizolid and other comparators were observed. Results were 
similar when limited to intent-to-treat (ITT) or microbiological ITT analysis popula-
tions. In an ad hoc analysis of MRSA-only populations, ORs for response were 1.0, 1.2, 
2.1, 1.1, 3.2, and 1.6 for tedizolid versus linezolid, ceftaroline, daptomycin, telavancin, 
tigecycline, and vancomycin, respectively. , . Absolute rates of discontinuation due to 
AEs ranged from 0.3% [0%, 49%] for tedizolid to 1.2% [0%, 81%] for telavancin, but no 
comparisons reached statistical significance. Results from fixed and random effects 
models generally were consistent. CONCLUSIONS: These findings suggest that tedi-
zolid offers an alternative treatment option for serious skin infections caused by 
suspected or documented MRSA. This study is subject to limitations inherent to all 
NMAs, and the results should be interpreted accordingly.
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clINIcal coMParISoN of full courSe INtraveNouS or abbrevIated 
oral aNtIbIotIcS IN HoSPItalIzed PatIeNtS wItH MetHIcIllIN-
reSIStaNt S. aureuS (MrSa) SkIN aNd Soft tISSue INfectIoNS
Jacobs DM1, Hsiao CB2, Paladino JA1
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OBJECTIVES: Orally active MRSA drugs are utilized in hospitalized patients for 
treatment of skin infections to abridge intravenous (IV) therapy, but clinical evi-
dence of their effectiveness is needed. Our goal was to compare health outcomes 
in hospitalized adult patients treated with a full course of IV or abbreviated oral 
antibiotics for MRSA skin infections. METHODS: This was a single center, retro-
spective cohort study of hospitalized patients with culture positive MRSA skin 
infections managed from 2009-2013. Patients were stratified based on receipt of 
full course IV antibiotics or abbreviated oral antibiotics during the hospital stay. 
Treatment failure was defined as one of the following within 90 days of initiation 
of treatment: 1. additional MRSA culture from any site, 2. change in antibiotic 
therapy, 3. secondary incision and drainage. Statistical analysis included multivari-
ate logistic regression models to assess for predictors of failure. RESULTS: Among 
101 patients with MRSA skin infections, 60 received a full course of IV antibiotics 
and 41 converted to oral antibiotics (minocycline or doxycycline [n= 34]). Treatment 
failure at 90 days was 35%, occurrence of failure was similar among patients with 
a full course of IV therapy and those abbreviated to oral therapy (21 of 60 [35%] vs. 
14 of 41 [34%], p = 0.93). The length of IV therapy was significantly less in patients 
treated with oral therapy (6.5 days vs 4 days, p< 0.01). In the multivariate adjusted 
model, treatment with oral antibiotics was not associated with failure. Predictors 
of failure included Hispanic ethnicity (aOR 15.8; 95% CI, 1.8-138.9, P = 0.01) and a 
trend towards significance for ulcer skin infections (p = 0.052). CONCLUSIONS: 
Although hospitalized patients are commonly treated with full course IV antibi-
otics for MRSA skin infections, we found similar outcomes in those converted to 
oral antibiotics. Treatment failures were associated with Hispanic ethnicity and 
ulcer skin infections.
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reSPIratory related HoSPItalIzatIoNS IN PreMature INfaNtS 
ProPHylaxed wItH PalIvIzuMab IN tHe caNadIaN regIStry of 
PalIvIzuMab (careSS)
Abraha H.Y.1, Li A.1, Paes B.2, Mitchell I.3, Lanctôt K.1
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BACKGROUND: The efficacy and safety of palivizumab for respiratory syncytial 
virus (RSV) prophylaxis in healthy premature infants ≤ 35 weeks gestational age 
(WGA), was confirmed in the IMpact, randomized trial. However, there are lim-
ited data on the incidence of hospitalization for respiratory related events in 
prophylaxed infants in the lower GA sub-categories. OBJECTIVES: The primary 
objective is to evaluate the incidence of respiratory illness (RIH) and RSV-specific 
hospitalizations (RSVH) in high-risk premature infants who received palivi-
zumab. METHODS: Data were collected from premature infants ≤ 35 completed 
WGA enrolled in the CARESS registry, who received at least one palivizumab injec-
tion between the 2005-2014 RSV seasons. Palivizumab utilization, compliance, 
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cine for use in immunocompetent adults aged 60 years and older, HZ continues to 
impact the American public and a better understanding of its current incidence 
is needed. METHODS: This was a retrospective analysis using the Truven Health 
MarketScan® databases from 2011. Cases were identified by a diagnosis code for 
HZ (ICD-9-CM: 053.xx) and must have been enrolled as of January 1, 2011, lacked 
a claim for shingles vaccination or HZ in the 90 days prior to this date, and been 
deemed immunocompetent according to the study criteria. Annual incidence rates 
were calculated for the entire population observed in the database as well as by 
gender and age group; standardized incidence rates were also produced using the 
2010 U.S. Census data. RESULTS: The annual incidence rate of HZ across all ages 
of the study population in 2011 was 4.47 per 1000 person-years (95% CI: 4.45, 4.50). 
This rate increased monotonically with age, ranging from 0.86 (95% CI: 0.84, 0.88) 
for those aged ≤ 19 to 12.78 (95% CI: 12.49, 13.07) for immunocompetent enrollees 
aged 80 and older. The incidence rate was 8.46 (95% CI: 8.39, 8.52) among adults 50 
years and older and 10.46 (95% CI: 10.35, 10.56) among those aged 60 years and older. 
The annual incidence rate of HZ was higher in women than men ((5.25, 95% CI: 5.21, 
5.29 and 3.66, 95% CI: 3.62, 3.69), respectively) and was seen across all age groups. 
When standardized using 2010 U.S. Census data, the annual incidence rate was 4.63 
per 1000 person-years (95% CI: 4.61, 4.66). CONCLUSIONS: Herpes zoster remains 
common among immunocompetent adults with incidence rates of HZ observed to 
increase with age and be higher in women than men.
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exaMINatIoN of HoSPItal-acquIred INfectIve eNdocardItIS uSINg 
MedIcare claIMS data
Wang Z., Zhang Q., Miyasato G.
Trinity Partners, LLC, Waltham, MA, USA
OBJECTIVES: Infective endocarditis (IE) is one of the most common hospital-
acquired infections. This study used Medicare claims data to understand the cur-
rent hospital-acquired infective endocarditis (HAIE) burden and associated risk 
factors. METHODS: The analysis was conducted using 2011 and 2012 Centers for 
Medicare and Medicaid Services Part A fee-for-service claims. Patients with an IE 
ICD-9 diagnosis code in 2012 and at least 6-months of follow-up were included. HAIE 
was defined as IE with 1) onset ≥ 72 h after admission or 2) a significant invasive 
procedure performed during a hospitalization ≤ 8 weeks before the onset. To meas-
ure the impact of HAIE versus non-HAIE on medical costs, a generalized estimat-
ing equation approach with a gamma distribution and log link function was used. 
Logistic regression was used to assess patient demographics’ and comorbidities’ 
association with HAIE. RESULTS: 10,059 IE patients were identified, 27% of which 
had HAIE. The 6-month death rate of HAIE patients was higher than non-HAIE 
patients (43% vs. 32%, p< 0.0001). HAIE patients had more hospitalizations (7.1 vs. 
3.9, p< 0.0001) and longer lengths of stay (27.7 vs. 14.1 days, p < 0.0001) after their 
IE onset. After adjusting for demographics, pre-existing health status (measured 
by Charlson Comorbidity Index) and hospital-level factors, HAIE patients had sig-
nificantly higher 6-month medical costs than non-HAIE patients (mean = $97,226 
vs. $39,032, p< 0.0001).Patients with liver disease or hemiplegia were at the high-
est risk of HAIE, with odds ratios of 1.9 and 2.6, respectively, while adjusting for 
covariates. CONCLUSIONS: Medicare HAIE patients had higher healthcare costs, 
underscoring the need to further understand the risk factors for hospital versus 
community-acquired IE. Our study showed that patients with certain pre-existing 
comorbidities have a higher risk of HAIE. Using this information, healthcare pro-
viders may be able to better prevent HAIE and avoid its associated mortality risk 
and costs.
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oNce-daIly SINgle-tablet regIMeN reduce loSS to follow-uP IN 
PeoPle lIvINg wItH HIv
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OBJECTIVES: Determine the factors associated with loss to follow-up (LTFU) in 
people living with HIV on antiretroviral therapy (HAART) in Mexico. METHODS: 
A case-control study in people living with HIV on HAART was conducted using 
the national database of the System of management, logistic and monitoring of 
antiretroviral (SALVAR) of the National Center for the Prevention and Control of 
HIV and Aids (CENSIDA). Subjects included in the study had begun HAART with at 
least 18 years age, between January 2009 and December 2013. LTFU was defined as 
not attending the clinic for a period of 6 months or longer, while not yet classified 
as dead or transferred-out. Patients in HAART until the end of the study or dead 
during treatment were considered to be controls. The unmatched sample size was 
estimated with a 95%CIs and 1:2 ratio of cases-to-control. A simple random sam-
pling technique was used to select the sample cases and controls (330 cases and 
660 controls). A logistic regression analysis was run using Stata 11.1. RESULTS: In 
multivariable analysis the time between the diagnostic and linkage to care ≥ 50 days 
(OR 1.87; 95%CIs 1.29-2.73) was associated with LTFU (p< 0.05). Once-daily single 
tablet regimen (OR 0.33; 95%Cis 0.23-0.46), age of start of treatment ≥ 41 years old 
(OR 0.57; 95%CIs 0.39-0.83), 4th year since linkage to care (OR 0.11; 95%CIs 0.04-0.29) 
compared to first year, and last viral load < 50 RNA copies/mL (OR 0.24; 95%CIs 
0.17-0.33) had reduced odds of being LTFU. CONCLUSIONS: Number of pills per 
day had a significant impact on the risk to LTFU and an undetectable viral load had 
a positive feedback in the retention to treatment. The data reflects the importance 
of continuing research on co-formulated antiretroviral regimens.
PIN29
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hospital-based outpatient wound centers. Patient, wound and encounter level char-
acteristics were examined. Treatment of interest was enzymatic debridement with 
clostridial collagenase ointment (CCO). RESULTS: A total of 9,203 patients, 20,358 
wounds, and 149,680 encounters for PU were identified. The majority of patients was 
female (51.0%), Caucasian (70.0%), and reported Medicare as their primary insurance 
(59.6%). Average age was 67.4 (SD= 19.5) and average number of physician visits was 
11.3 (SD= 14.9). Mean wound surface area was 8.8 cm2 (SD= 30.3). Overall average 
wound duration was 4.3 months (SD= 16.6). Of the 20,358 wounds, approximately 19.8 
% received CCO (n= 4,022). The majority of wounds treated with CCO were Stage III and 
IV (60.1% and 29.6%, respectively). Wounds treated with CCO had significantly more 
(p< 0.001) debridements of all methods (4.8, SD= 5.9) relative to the overall population 
(3.7, SD= 6.3). Problems treated with CCO were significantly more likely (p< 0.0001) 
to have an infection (65.3%) compared to the overall PU population (51.5%). Average 
number of visits where CCO was administered was 7.4 (SD= 5.9) and the average 
days of use with CCO was 53.3 days (SD= 58.0). Average number of CCO tubes used by 
patients was 2.2 (SD= 0.6). Mean days in service for CCO-treated wounds was 127.9 
(SD= 159.8), which was significantly higher compared to days in service for non-CCO 
treated wounds (98.9, SD= 157.7). CONCLUSIONS: Wounds treated with CCO had sub-
stantially longer days in service, more likely to receive debridement of all methods, 
and more likely to be infected relative to the overall PU population. Results from this 
analysis indicate that healthcare providers are using CCO in Stage III and IV PUs.
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lINezolId PreScrIPtIoN PatterN: IdeNtIfyINg tHe uSe to ratIoNalIze 
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OBJECTIVES: Linezolid is an important antimicrobial strategy to combat methicillin-
resistant Staphylococcus aureus (MRSA). However, it should be used with caution 
due to its high cost and to avoid the development of resistant strains. This study 
sought to determine the pattern of use of Linezolid in a large hospital in Fortaleza, 
Brazil. METHODS: This was a cross-sectional study carried out from 2013 to 2014, 
in which data were collected from the medical records of 170 patients admitted to 
medical wards and intensive care units of a general hospital and that were in use of 
Linezolid. The pharmacotherapeutic and microbiological parameters followed the 
Antimicrobial Stewardship Guideline (Infectious Diseases Society of America, 2012) by 
pharmacist and medical infectious disease team. For the calculation of the direct cost, 
the electronic source Brasíndice was used. RESULTS: The patients were in use of this 
antimicrobial had a mean age of 74.5 years and 56% were female. The most isolated 
bacteria were Staphylococcus aureus (13; 72%), Enterococcus (4; 22%), Streptococcus 
pneumoniae (1; 6%) and the most verified types of infection were pulmonary (137 
/ 64.32%), urinary (22 / 10.33%) and skin (9/4.22%). The average load time was 11.3 
days. The overall cost of the therapy with Linezolid was $216,075.41. CONCLUSIONS: 
Linezolid is strategic in the treatment against MRSA, especially in pneumonia, but 
should be used rationally to avoid adverse effects and increase of unnecessary costs. 
Thus, the determination of its pattern of use was a fundamental step to achieve better 
clinical outcomes in the multidisciplinary team setting.
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OBJECTIVES: Identify patient and clinical characteristics in the venous leg ulcer (VLU) 
population and examine patterns of enzymatic debridement utilization. METHODS: 
Retrospective, de-identified electronic medical records from 2007-2013 were extracted 
from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 hos-
pital-based outpatient wound centers. Patient, wound and encounter level charac-
teristics were examined. The treatment of interest was enzymatic debridement with 
clostridial collagenase ointment (CCO). RESULTS: A total of 9,091 patients, 25,734 
wounds, and 222,666 encounters for VLU were identified. The majority of patients was 
male (50.5%), Caucasian (74.1%), and reported Medicare as their primary insurance 
(53.4%). The average age was 68.9 (SD= 14.6) and the average number of physician 
visits was 17.7 (SD= 22.5). The mean wound surface area was 16.5cm2 (SD= 44.6). The 
overall average wound duration was 5.8 months (SD= 26.7). Of the 25,734 wounds, 
approximately 12.7% received CCO (n= 3,278). Wounds treated with CCO had sig-
nificantly more (p< 0.001) debridements of all methods (5.5, SD= 7.6) relative to the 
overall population (3.4, SD= 5.5). Problems treated with CCO were significantly more 
likely (p< 0.0001) to have an infection (74.2%) compared to the overall VLU population 
(60.5%). The average number of visits where CCO was administered was 2.1 (SD= 6.7) 
and the average days of use with CCO was 13.3 days (SD= 46.2). The average num-
ber of CCO tubes used by patients was 1.0 (SD= 1.1). Mean days in service for CCO-
treated wounds was 148.2 (SD= 196.5), which was significantly higher compared to 
days in service for non-CCO treated wounds (79.0, SD= 135.6). CONCLUSIONS: Wounds 
treated with CCO had substantially longer days in service, were more likely to receive 
debridement of all methods, and more likely to be infected relative to the overall VLU 
population. Results from this analysis indicate that health care providers are using 
CCO in more severe, difficult-to-heal VLUs.
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OBJECTIVES: Herpes zoster (HZ), also known as shingles, is a painful and com-
monly occurring condition in the U.S.. In spite of a universally recommended vac-
